Amgen revenue up 9 percent
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”24-10-2011″ enddate=”24-04-2012″ width=”300″ height=”245″] Amgen’s total revenue shot up 9 percent during the first quarter of this year, the Thousand Oaks-based biotech giant said in an April 24 earnings report. The biotech company reported revenue of $4 billion, up from $3.7 billion in the first quarter of 2011. Total product Read More →
Read More →Amgen’s founding CEO dies
George Rathmann, the founding CEO of Thousand Oaks-based Amgen, has died, the company said April 23. Born in 1927, Rathmann helmed what is now Ventura County’s largest private-sector employer from 1980 to 1988 and was the chairman of the board until 1990. He had been recruited by Bill Bowes, one of Amgen’s founders, to run Read More →
Read More →Amgen to buy KAI for $315M
Amgen said April 10 that it plans to buy San Francisco-based KAI Pharmaceuticals for $315 million in cash in a deal that would give it worldwide rights to an experimental treatment for patients with chronic kidney disease. Thousand Oaks-based Amgen said the deal would give it worldwide rights, excluding in Japan, to KAI’s lead product, Read More →
Read More →Amgen, AstraZeneca strike drug development deal
Amgen has entered a development deal with London-based AstraZeneca to jointly commercialize five anti-inflammation drugs. Under the terms of the agreement announced April 2, AstraZeneca will pay a one-time $50 million payment to Amgen and will be responsible for helping the Thousand Oaks-based biotech giant commercialize its inflammation drug pipeline. The firms said in a Read More →
Read More →
Amgen looks for new life with Micromet
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen Q4 earnings drop 8.5%
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”26-07-2011″ enddate=”26-01-2012″ width=”300″ height=”245″] Biotech giant Amgen, which said earlier on Thursday that it would pay $1.2 billion for leukemia drugmaker Micromet, reported fourth-quarter earnings that missed analyst expectations. The Thousand Oaks-based company said fourth-quarter profits fell 8.5 percent to $934 million, or $1.08 per share, on lower sales of Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
